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Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is an uncommon cardiac ion channelopathy charac-
terized by polymorphic or bidirectional ventricular tachy-
cardia (VT) during physical or emotional stress.1 The
proband often presents during childhood or early adoles-
cence with syncope, seizure, or cardiac arrest.2 In some
cases, sudden unexpected death (SUD) can be the ﬁrst
manifestation of CPVT.3,4 In 2001, Priori et al5 discovered
that mutations in the cardiac ryanodine receptor 2 (RyR2), a
highly conserved ion channel, underlie most cases of CPVT.
The diagnosis is made on the basis of history, exercise stress
testing (EST), and genetic testing.5
The management of CPVT is challenging. Classically,
beta blockers are used to suppress arrhythmia,1,2 although
nonadherence and treatment failure commonly occur.3,4
Flecainide is a promising second-line agent in CPVT.6
Patients with refractory arrhythmia or aborted cardiac arrest
may be referred for an implantable cardioverter-deﬁbrillator
(ICD).5 Recently, a multicenter study showed beneﬁt from
left cardiac sympathetic denervation (LCSD).7 The presented
case describes a very young child with a unique trigger for
cardiac arrest in CPVT.
Case description
A previously healthy 4-year-old male child had a witnessed
cardiac arrest at home. Prior to the event, the boy was eating
macaroni and playing with his brother. While trying to climbKEYWORDS Catecholaminergic polymorphic ventricular tachycardia; Sudden
death; Child
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).onto his brother’s back, he suddenly became unresponsive
and fell to the ﬂoor. Assuming that he had aspirated, his
mother administered rescue breaths and called emergency
services. Paramedics arrived on scene promptly and found
the victim to be in pulseless polymorphic VT. Cardiopulmo-
nary resuscitation, intravenous epinephrine, and several
deﬁbrillations were initiated. A piece of macaroni was found
lodged inside the boy’s trachea during endotracheal intuba-
tion. He regained a perfusing rhythm after approximately 10
minutes of resuscitation. He was hemodynamically stable
and neurologically intact on arrival to the hospital. Electro-
cardiography demonstrated frequent multifocal premature
ventricular complexes (PVCs). The emergency physician
initiated mechanical ventilation and administered intrave-
nous morphine and midazolam for sedation. A single dose of
broad-spectrum antibiotic was given for empiric coverage of
aspiration. He was cooled to 341C for 48 hours as per
institutional protocol and urgently transferred to the provin-
cial tertiary care pediatric hospital.
That evening, the boy arrived in our pediatric intensive
care unit (PICU) with a presumed diagnosis of hypoxia-
induced cardiac arrest secondary to aspiration. However, the
patient experienced recurrent, unexplained polymorphic VT
during the ﬁrst night of admission (Figure 1). These episodes
frequently deteriorated into VF cardiac arrest necessitating
amiodarone infusion and external deﬁbrillation on 5 separate
occasions. The following day, the patient continued to have
runs of bigeminy and polymorphic VT (Figure 2). The
consulting cardiac electrophysiologist suspected electrical
storm secondary to a catecholamine-sensitive channelopathy
and advised against repeated deﬁbrillation. The initiation of
intravenous esmolol suppressed the patient’s polymorphic
VT.
Diagnostic tests performed during PICU admission
included normal chest radiographs, transthoracic echocar-
diography, and cardiac magnetic resonance imaging. Serum
troponin level on presentation was mildly elevated in the
context of recent cardiac arrest and deﬁbrillation. All other
investigations, including electroencephalography, computed
tomography scan, and magnetic resonance imaging of the
brain, were normal. Subsequent resting electrocardiogramspen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.08.007
KEY TEACHING POINTS
 Catecholaminergic polymorphic ventricular
tachycardia (CPVT) is a rare diagnosis. Key features
on clinical history include syncope and aborted
cardiac arrest in young patients during times of
exertion or extreme emotion. Prompt diagnosis is
essential, as life-saving treatments exist, even
during acute ventricular arrhythmias at time of
presentation.
 Adrenergic triggers of cardiac events typically
include competitive sports and sudden extreme
emotions. However, other triggers exist, such as
swimming, which may be particularly dangerous
because drowning may follow a cardiac event.
Clinicians need be aware that a variety of triggers
may exist in CPVT. Polymorphic ventricular
tachycardia in the young should always prompt
evaluation for inherited arrhythmia.
 CPVT is often an inherited disorder. Standard family
evaluation should include exercise testing in all
cases and genetic testing in genotype-positive
CPVT, even in the absence of symptoms.
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prolongation seen transiently in 1 tracing (460 ms). The boy
made a full neurologic recovery and was transitioned to oral
propranolol (2 mg/kg/day) while on the cardiac ward.Figure 1 Resting electrocardiogram demonstrating bidirectional ectopy de
cardioversion during intensive care unit admission.One week after discharge, he was asymptomatic with a
normal repeat transthoracic echocardiogram and resting
ECG. An outpatient 24-hour Holter monitor revealed fre-
quent PVCs and bidirectional couplets while on propranolol.
There was no evidence of supraventricular arrhythmia on any
study. He was transitioned to nadolol (1.2 mg/kg/day) as an
outpatient. Sequencing of RYR2, calsequestrin 2, and
inwardly rectifying potassium channel 2 were performed
and a novel variant (A2317T) was identiﬁed in RYR2,
classiﬁed as probable disease-causing for CPVT. No other
genetic variants were identiﬁed.
Family history was negative for syncope, seizures, SUD,
unexplained fatal accidents, and drownings. Genetic and
exercise testing was unremarkable in both parents. The boy’s
12-year-old brother was not genetically screened, as he was
considered low risk of the basis of negative parental testing.
At 2-year follow-up, the proband described remains asymp-
tomatic on nadolol (1.3 mg/kg/day). No one else in the
family has developed a phenotype consistent with CPVT in
the interim.Discussion
CPVT is an important cause of aborted cardiac arrest and
SUD in the young. We describe a case involving one of the
youngest known symptomatic subjects and demonstrate a
unique trigger for cardiac arrest. Classic precipitants of
arrhythmia in CPVT are athletics2 and emotional circum-
stances.3 Less-recognized precipitants of arrhythmia include
swimming,8 inappropriate ICD discharge,9 and atrial ﬁbril-
lation.10 Life-threatening events in CPVT may even occurgenerating into polymorphic ventricular tachycardia prior to electrical
Figure 2 Resting electrocardiogram demonstrating bigeminy during intensive care unit admission.
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which the trigger for cardiac arrest is unique and controver-
sial. Ostensibly, the patient had an aspiration and choking
event resulting in a respiratory-induced cardiac arrest.
Alternatively, the aspiration event may have caused a
catecholamine surge leading to an arrhythmic cardiac arrest,
or the patient’s polymorphic VT may have been precipitated
merely by exertional play, with the foreign body lodged in
his trachea being an incidental ﬁnding. Regardless, a
polymorphic VT arrest in a young patient should prompt
the clinician to consider CPVT even if alternative explan-
ations, such as hypoxia, seem more likely.
Iatrogenic triggers must also be considered in every case
of CPVT. ICD discharges can heighten catecholamine
release and propagate electrical storm.3,11 As observed in
this case, external deﬁbrillation in the PICU worsened
ventricular arrhythmia. The electrophysiologist instead used
intravenous esmolol to suppress catecholamine release.
Limited evidence has also indicated that intravenous propra-
nolol and verapamil may be effective options under these
circumstances.12,13 Guidelines suggest ICD placement for
secondary prevention as a class I recommendation.5 How-
ever, the risks of ICD discharges in CPVT are substantial and
life-threatening.3,11 In this case, we decided against ICD
placement after the documented recurrent VF and shocks
during the patient’s initial course, and the subsequent
excellent response to beta blocker therapy. This approach
should be considered in all new diagnoses of CPVT.
Providers, patients, and their family should be aware of the
risks and beneﬁts of ICD implantation unique to CPVT.
Initiation of adjunct therapies, such as ﬂecainide and LCSD,
are safer, are possibly more effective, and should bediscussed early on.5–7 Recent data support the early adoption
of LCSD either before or at the time of ICD surgery.7
Our evaluation for suspected CPVT was also atypical. We
used Holter monitoring, rather than EST, as young children
often lack the coordination required to safely use a treadmill.
The Holter monitor demonstrated frequent polymorphic
PVCs during exertion, which alone does not meet consensus
diagnostic criteria5 for CPVT but raises suspicion for
arrhythmia substrate. This approach may be useful in
patients with equivocal EST, or those unable to exercise
owing to deconditioning, comorbidities, or age. Holter
monitoring should not be routinely used in lieu of EST, as
detection of classic CPVT-associated arrhythmias may be
lower in nonexertional testing. Treadmill testing has also
been shown to be negative in gene-positive carriers that
subsequently developed symptoms.14
CPVT typically manifests during early adolescence2,3,5
and is complicated by substantial diagnostic delay despite
life-threatening events,3 in part because the resting ECG is
typically normal. There is little data on very young children
with CPVT. We demonstrate that arrhythmia related to
CPVT can occur early in life, especially under an extreme
physiologic stress. To our knowledge, we describe a novel
variant in (A2317T) in the Central-forming domain on
RYR2 localizing to the second hotspot on the cytosolic side
of the receptor. Numerous mutations underlying CPVT
have been described in this area of RYR2.14 As frequently
seen in severe childhood diseases like CPVT, this boy also
harbored a de novo variant. This evidence, coupled with a
pathognomonic phenotype, suggests a high likelihood of
pathogenicity. Literature suggests that children presenting
early in life and male subjects with RYR2 mutations may be
497Roston et al Unusual Presentation of CPVTat highest risk of life-threatening events and treatment
failure.2,3
The family assessment should focus on eliciting clues of
CPVT in each pedigree, including syncope, presyncope,
seizures, unexplained drownings, or motor vehicle–related
deaths. In addition, EST and genetic testing should be
performed in both parents whenever possible. This is of
paramount importance, as a bimodal age distribution has
been described in CPVT.15 The boy’s older brother was not
clinically or genetically tested based on negative parental
testing.
This case is reported to demonstrate that unusual triggers
for cardiac arrest exist in CPVT. A careful history, clinical
evaluation, and molecular testing can improve the substantial
delay to diagnosis described in CPVT. Prompt initiation of
treatment can be life-saving. Clinicians should be aware that
newer therapeutic options for managing CPVT exist.4,7
Further studies are needed to better understand phenotype–
genotype correlations in children and families with CPVT.
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